Non-Small Cell Lung Cancer (NSCLC) | Topics

Osimertinib Plus Bevacizumab Did Not Prolong PFS in Patients With EGFR T790M–Mutated NSCLC
January 26, 2021

Though previous reports have suggested that an EGFR tyrosine kinase inhibitor plus an anti-VEGF agent might offer benefit to patients with brain metastasis or pleural effusion, the study authors could not identify its advantage.

FDA Grants Breakthrough Therapy Designation to Tiragolumab Combo for PD-L1-High NSCLC
January 05, 2021

The combination of tiragolumab and atezolizumab (Tecentriq) was granted breakthrough therapy designation based on promising efficacy and safety data observed in the phase 2 CITYSCAPE trial.

FDA Grants Priority Review to sNDA for Lorlatinib in Previously Untreated ALK+ NSCLC
January 04, 2021

Under the FDA’s Real-Time Oncology Review Pilot Program and Project ORBIS, the FDA is reviewing a supplemental new drug application for lorlatinib (Lorbrena) as a first-line treatment for patients with ALK-positive metastatic non–small cell lung cancer.